Monday, 18 Mar 2019

You are here

Mortality and Hospitalization with Pulmonary Hypertension in Systemic Sclerosis

PHAROS is a prospective cohort studying the natural history of pulmonary hypertension (PH) in systemic sclerosis (SSc). They have shown that risk factors for poor outcomes in this cohort included male sex, DLCO < 50%, exercise oxygen desaturation, and pericardial effusions. 

They identified 236 at-risk for PH patients from this population (ECHO systolic pulmonary arterial pressure > 40 mmHg, or DLCO < 55% predicted or ratio of % forced vital capacity/%DLCO > 1.6, measured by pulmonary function testing).

This cohort was followed for 4 years (range 0.4–8.5 yrs), and 35/236 (15%) developed PH after entry (PH group).

In the at-risk group, higher mortality was strongly associated with male sex, low %DLCO, exercise oxygen desaturation, anemia, abnormal dyspnea scores, and baseline pericardial effusion.

PH patients with DLCO < 50% had the highest risk of cardiopulmonary hospitalizations.  Other risks for cardiopulmonary hospitalization were \increased dyspnea and pericardial effusions.

Identification of this at risk group should lead to closer monitoring, ECHO and possibly right heart catheterization to receive appropriate intervention.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Brazilian Guidelines for Systemic Autoimmune Myopathies

The Myopathy Committee of the Brazilian Society of Rheumatology (BSR) has put forward recommendations for the management of patients with systemic autoimmune myopathies (SAM).

The challenge has been that there is a paucity of effective controlled clinical trials, and hence, glucocorticoids (GC) have played a first-line and prominent role in the treatment of SAM.

EULAR Consensus Guidelines for Juvenile Localized Scleroderma

A EULAR international committee of 15 experts in pediatric rheumatology have established consensus-based recommendations for the management of juvenile localised scleroderma (JLS).

JLS is an uncommon disorder that is commonly seen by pediatric and adult rheumatologists. Evidence-based guidelines are sparse and management is mostly based on physicians’ experience.

2018 Swedish Guidelines for Giant Cell Arteritis Treatment

The Swedish Society of Rheumatology has developed evidence-based guidelines for the management of giant cell arteritis (GCA) with a focus on the appropriate use of corticosteroids and tocilizumab. 

Congenital Heart Block: Dangers Ahead

Children of autoantibody-positive mothers who were born with congenital heart block were at high risk for developing later cardiovascular and autoimmune disorders, as were their siblings, Swedish researchers reported.

Lower Mortality Results from Lower Activity in Lupus

Data from the longitudinal Tromsø Lupus Cohort study has shown that lupus patients who achieve a Lupus Low Disease Activity State (LLDAS‐50) were shown to have significantly less severe damage, and a reduction in mortality. This was a population‐based study of SLE patients in the northern‐most counties of Norway.